NEW YORK, July 8, 2026, 13:02 (EDT)
- Catheter Precision, Inc. NYSEAMERICAN:VTAK last traded around $1.43, up roughly 101%. Volume was over 166 million shares.
- Traders jumped on Flyte after its LifeVac tie-up, and July 6 patent news kept attention on the medical-device theme.
- The July 2 amended S-1 covers 68.1 million shares for resale. The company had 3.6 million common shares outstanding as of July 2.
At 13:02 EDT in New York, trading stayed within the NYSE main session from 9:30 a.m. to 4:00 p.m. ET. VTAK was moving on its own, not with the group. Shares were last seen near $1.43, up about 101%. Volume hit 166.6 million against a market cap of under $4 million.
| Instrument | Last | Day move | Market read |
|---|---|---|---|
| Catheter Precision, Inc. NYSEAMERICAN:VTAK | $1.43 | +100.6% | Sharp move on news |
| SPDR S&P 500 ETF Trust NYSEARCA:SPY | $744.03 | -0.5% | Broad market off |
| iShares Russell 2000 ETF NYSEARCA:IWM | $292.87 | -1.1% | Small caps falling more |
| SPDR S&P Biotech ETF (NYSEARCA:XBI) | $161.14 | -1.7% | Biotech sentiment fading |
| iShares U.S. Medical Devices ETF (NYSEARCA:IHI) | $51.58 | -1.3% | Devices trade heavy |
The tape looks more like a low-float pop than a clean move in the electrophysiology business. Google Finance showed 166.61 million shares traded, with average volume at 6.96 million and 2.69 million shares out. That’s about 24 times average and 62 times the shares out.
Flyte, the regional air unit of Catheter, was the latest focus. On July 7, Flyte said every Cirrus Vision Jet in its line-up will now include LifeVac airway-clearance devices. “Safety isn’t one feature. It’s a system,” said Flyte founder Marc Sellouk. Arthur Lih, who started LifeVac and serves as CEO, said choking “happens fast.” The announcement left out any details on how much the order is worth, what the fleet could bring in, or the margin. GlobeNewswire
The patent release put the stock back in the headlines for medical investors. CEO David Jenkins said, “VT is not well treated today,” adding that the VIVO project offers doctors a “GPS-like map.” Jenkins called heart failure one of “the costliest maladies worldwide” when talking about Cardionomix. According to the release, VIVO holds 18 patents and applications, while Cardionomix has 33. BioSpace
Scale remains a problem. Catheter Precision brought in $432,000 in revenue in the first quarter—$248,000 from products, $184,000 from services. Net loss hit $1.69 million. Net loss to common stockholders was $3.04 million after factoring in a deemed dividend from a warrant inducement.
Cash adds to the challenge of valuing the rally. The March 31 balance sheet listed $441,000 in cash and cash equivalents, current assets of $1.249 million, and $19.738 million in current liabilities. The 10-Q warned of substantial doubt about the company’s ability to keep operating for 12 months from when the statements came out.
| Item | Market-positive read | Market brake |
|---|---|---|
| July 7 Flyte-LifeVac deal | Adds a safety device in the aviation business | No word on revenue, order size, or margin |
| July 6 patent release | Adds some IP around VIVO and Cardionomix | Holding patents does not mean sales |
| Q1 2026 results | Revenue increased to $432,000 | Losses and cash use are still high |
| July 2 S-1/A | Registers shares from prior financing and buyouts | 68.1 million resale shares versus 3.6 million current shares |
The S-1/A puts 68,067,042 shares on file, covering common shares plus conversion shares for Series C, Series D, Series J preferred stock, and Series M warrants. All proceeds from any sales go to the selling stockholders, not the company. The filing also cautions that issuing these shares could lead to substantial dilution.
The company’s own July 2 table showed 3,609,471 common shares outstanding. The registered amount is about 18.9 times higher. The filing says selling stockholders can sell all, some, or none of their shares. That doesn’t mean all shares hit at once, but when a $3 million to $4 million company trades over 160 million shares by midday, supply risk jumps out.
Next up are the standard checks: Q2 Flyte revenue, use of the aircraft, how medical-device orders turn into revenue, cash, and any news on the resale registration. Once the S-1/A goes effective, investors can sell shares on exchanges, OTC, in blocks, in private deals, or short after the effective date. That’s the next supply traders have to price.
